



Sobi and Kineret[®] are trademarks of Swedish Orphan Biovitrum AB (publ).
 www.sobi.com
 HCC-2183 - September 2018



© 2018 Swedish Orphan Biovitrum AB (publ) - All rights reserved.

Call for Safety Reporting

Suspected Adverse Drug Reactions (side effects) or medication errors may be reported using the Medicines Authority ADR reporting form, which is available online at: <http://www.medicinesauthority.gov.mt/adrportal> and sent by post or email to:
 P: Pharmacovigilance Section at Post-Licensing Directorate, Medicines Authority, Sir Temi Zammit Buildings, Malta Life Sciences Park, San Gwann SGN 3000
 E: postlicensing.medicinesauthority@gov.mt

Alternatively, the contact details of the company may be used for reporting:
 Sobi I&E; E-mail: safety@pharmassist.gr; Tel: 00302106561435

FOLD

FOLD

TREATMENT WITH KINERET[®]

Patient's name:

Caregiver's name (for children):

Patient's dose:

Physician's name and phone number:



Important safety information regarding Still's disease

Macrophage activation syndrome (MAS) is a serious complication of Still's disease. Left untreated MAS can be life threatening. The risk for developing MAS is increased if you have an infection or if your Still's disease symptoms are poorly controlled. Symptoms of MAS can be e.g. persistent high fever, swelling of lymph nodes, and persistent rash.

Kineret® (anakinra) can increase the risk for a serious infection. Symptoms might be persistent high fever, shivers, cough, headache, and redness and tenderness of the skin. Also, persistent low-grade fever, weight loss, and persistent cough can be signs of an infection.

If you develop signs of an infection or worsening of your Still's disease symptoms you should contact your health care provider as soon as possible.